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The cancer community understands the value of blood profiling
measurements in assessing and monitoring cancer. We describe an
effort among academic, government, biotechnology, diagnostic, and
pharmaceutical companies called the Blood Profiling Atlas in Cancer
(BloodPAC) Project. BloodPAC will aggregate, make freely
available, and harmonize for further analyses, raw datasets, relevant
associated clinical data (e.g., clinical diagnosis, treatment history,
and outcomes), and sample preparation and handling protocols to
accelerate the development of blood profiling assays.
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The main goal of Precision Medicine
(PM) is the customization of healthcare,
with medical decisions, practices, and/or
products being tailored to an individual
patient. Several national efforts, such as the
Precision Medicine Initiative (PMI),1 are
working to integrate PM into biomedical
research, drug and diagnostic test develop-
ment, and patient care to achieve the
highest levels of accuracy and precision in
the treatment of a patient. Multiple PM
stakeholders, including patients, physicians,
healthcare administrators, regulators, and
payers are hoping for: 1) breakthrough
therapies; 2) breakthrough diagnostics; and
3) greater value to patients and the health-
care system by achieving superior clinical
outcomes through identification of patients
most likely to benefit, thereby sparing the
drug toxicities and high cost associated with
ineffective treatments. Thus far, oncology
has been one of the biggest beneficiaries of
PM, where cancers once perniciously pro-
gressive have been significantly slowed, and
even cured, through the use of evolving
technologies that enable the matching of
therapies to an individual’s tumor biology.
Thanks to these significant scientific
advances, we know that tumors shed cells
and a variety of chemical signals into the
bloodstream, leaving behind small hints
that can identify the cancer phenotype and
genotype, the organ of origin, and the evo-
lutionary state of cancer as a result of its
natural progression and/or treatment
pressures. For this reason, researchers are
especially interested in developing new
technologies to use this knowledge to
transform how we detect and diagnose can-
cer, and how we predict and monitor
response to therapeutic intervention. This
provides the foundation for a future where
simple blood draws could help physicians
and patients more accurately and success-
fully detect and manage the disease. This
approach, commonly described as liquid
biopsies, provides a less invasive, more easi-
ly replicable, and potentially more informa-
tive alternative to standard tissue biopsies.
Liquid biopsies are experienced by the
patient as a simple blood test as compared
to an often painful bone biopsy or more
invasive open biopsy under anesthesia.
The value of blood profiling measure-
ments in assessing and monitoring cancer
patient status includes: repeated access to
tumor material when tissue biopsies are
impractical, more comprehensive assess-
ment of tumor biology compared to sam-
pling of one specific tumor locus, and more
practical assessment of the molecular evolu-
tion of cancer throughout a patient’s treat-
ment. There has been significant academic
and commercial activity in the development
of liquid biopsies that are both cell-based,
such as circulating tumor cells (CTC), and
cell-free, such as circulating tumor DNA
(ctDNA), isolation and analysis platforms,
as well as technologies to assay for exosomes
and other extracellular vesicles.
At this time, two liquid biopsies have
been clinically validated and approved by
the US Food and Drug Administration
(FDA) as a companion diagnostic. Both
test for mutations in the EGFR gene for
patients with metastatic non-small cell
lung cancer (NSCLC). The cobas EGFR
Mutation Test v2 (Roche Molecular Sys-
tems, Nutley, NJ) tests for exon 19 dele-
tions or exon 21 (L858R) substitution
mutations in the EGFR gene to identify
patients eligible for treatment with Tarceva
(erlotinib).2 The same test also can detect
the T790M mutation in the EGFR gene
to identify patients for treatment with
Tagrisso (osimertinib).3
Clinicians are currently restricted in
their ability to include liquid biopsy analy-
sis as a part of clinical care (e.g., for serial
monitoring), other than for ctDNA single
draws, due to lack of sufficient evidence for
payer reimbursement. There is growing
concern that ctDNA analysis may follow
the same path as first-generation CTC
methods4 because the data needed to dem-
onstrate the level of evidence that the FDA
and payers believe is needed for clinical effi-
cacy currently exists for only the two indi-
cations just mentioned. While many blood
profiling platforms exist for research use
only (RUO), questions remain regarding
the performance characteristics and clinical
validation of these platforms, and standard
protocols for sample collection, processing,
and analysis remain to be established. This
information is a prerequisite to the design
of clinical studies to demonstrate clinical
utility.5 Akin to the concept used by The
Cancer Genome Atlas (TCGA) launched
in 2006, this foundational information can
be developed through collaboration across
stakeholders and sharing of very early-stage
research. Establishing a comprehensive
knowledge base in the liquid biopsy space
will provide an invaluable reference for
anyone entering the field, help develop the
evidence required to support clinical utility,
assay reproducibility, and provide support
for FDA approval and payer reimbursement.
Following the advent of the Cancer
Moonshot Initiative,6 the Blood Profiling
Atlas in Cancer (BloodPAC, http://
bloodpac.org) Consortium was launched on
October 17, 2016 to aggregate, make freely
available, and harmonize data for further
analysis: 1) data from CTC, ctDNA, pro-
teins including tumor associated autoanti-
bodies, and exosome assays; 2) associated
clinical data, such as clinical diagnosis, treat-
ment history and outcomes; and 3) sample
collection, preparation, and handling proto-
cols. This collaborative effort brings together
representatives from academia, private foun-
dations, industry, and the government to
accelerate the exploration, implementation,
and assessment of potential clinical utility of
liquid biopsies with the aim to understand
the temporal evolution of a patient’s disease.
Currently, 25 organizations are participating
in the Consortium, with additional mem-
bers joining in 2017.
The initial project goals were threefold.
First, participants have pledged and started
to contribute data that underpin the prea-
nalytical and analytical criteria for different
liquid biopsy test platforms. The second
goal is to develop a prototype BloodPAC
Data Commons and analysis cloud, which
will be based in part on the open source
software developed for the NCI Genomic
Data Commons and Cancer Genomics
Cloud Pilots.7 Data commons and analysis
clouds colocate the data, storage, and com-
puting infrastructure with commonly used
tools, applications and services to create
interoperable resources for the research and
clinical communities.7 With a data com-
mons and analysis cloud, researchers can col-
laboratively analyze data in a scalable and
reproducible manner using existing or novel
tools, without first downloading it and set-
ting up their own analysis environments.7
The BloodPAC Data Commons shares a
data model with the NCI Genomic Data
Commons and employs the same core web
services, such as those providing unique digi-
tal IDs for data, so that linking the two com-
mons and building applications that access
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Figure 1 BloodPAC Data Model.
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data from both is straightforward. The third
goal is for the BloodPAC team to summa-
rize the information from the commons to
provide a “how to” for the scientific/medical
community on the minimal criteria required
for establishing liquid biopsy testing in col-
laboration with the FDA and the College of
American Pathologists.
As a proof of concept, three working
groups of BloodPAC coordinated the initial
deposition of preanalytical datasets and sam-
ple preparation protocols. The Data Work-
ing Group, co-chaired by Robert Grossman
and Brandi Davis-Dusenbery, developed a
secure and compliant data commons (the
BloodPAC Data Commons) to store, ana-
lyze, and share the datasets, an initial data
model (Figure 1) for storing, accessing, and
querying the commons, data use agreements
that were completed by 13 of 23 stakehold-
ers during the first 60 days of the project,
and a preliminary version of a pipeline for
analyzing some of the submitted data. The
Technology Applications Working Group,
co-chaired by Peter Kuhn, Muneesh Tewari,
and John Simmons, is working alongside
the Samples Working Group, which is co-
chaired by Howard Scher, Craig Shriver,
and Anne-Marie Martin, to review the ana-
lytical and preliminary clinical assay valida-
tion methodology for data to be submitted
to the BloodPAC Data Commons. Collec-
tively, this first set of data will drive impor-
tant analysis on preanalytical assessments,
including questions about the specimen
before it is analyzed, such as specimen col-
lection, handling, processing, storage, and
annotation. This will provide a solid foun-
dation upon which future BloodPAC work
will build.
The BloodPAC Consortium is a unique
opportunity for the public, researchers, and
industry to all gain by collaboration. The
primary beneficiaries are patients who will
gain earlier access to blood-based tests to
detect and characterize cancer. Industry has
some of the most to offer, and gain, from
BloodPAC. Pharmaceutical, diagnostic, and
tool companies all have datasets to share.
Analysis companies have algorithms and
expertise to share. However, prior to the
BloodPAC, these groups had never been in
the same room, working on the same prob-
lems, together with government regulators
and academic researchers. Researchers also
stand to immediately gain from the Blood-
PAC. One of the most intractable problems
of modern science is the disincentive to pub-
lish negative results, causing researchers
around the world to repeat the mistakes of
their colleagues. The BloodPAC Consor-
tium is sharing very early-stage research
information about how to best collect and
analyze these specimens, and, critically, it is
also sharing what has not worked.
Moving forward, BloodPAC has as its
mandate to accelerate the development and
approval of liquid biopsy assays to improve
the outcomes of patients with cancer. To
do so, the BloodPAC Consortium will
develop and operate a collaborative infra-
structure that enables sharing of informa-
tion between stakeholders in industry,
academia, and regulatory agencies and to
conduct clinical validation studies designed
to improve the outcomes for patients with
cancer. The ultimate goal from this project
will be to create a “patient disease and
treatment path” so that the scientific and
clinical communities have a better under-
standing of how a disease progresses and
how to optimize the choice of therapy at
particular points in time. Thus, the Blood-
PAC Consortium could bring value to all
precision medicine stakeholders because:
1) patients may have access to easier, mini-
mally invasive, disease monitoring tools to
inform the best treatment decisions; 2) phy-
sicians may be able to monitor patients
more frequently and make more informed
decisions more rapidly; 3) assay developers
will have access to information that will
reduce their need to reproduce data that
already exists and to enable a focus on the
generation of new knowledge; 4) the sum-
mary of assay performance elements could
provide a foundation for liquid biopsy vali-
dation and qualification requirements to
meet regulatory approval; and 5) paths for
reimbursement of testing and treating will
be more apparent for payers. Precision
Medicine requires the close collaboration
between a complex system of stakeholders,
each of whom applies their expertise to bet-
ter understand and address the varied needs
of patients. Blood PAC is uniquely posi-
tioned through engagement of all stake-
holders to be successful in bringing liquid
biopsies into broad clinical care.
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